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ABSTRACT 
Seventy patients with psoriasis severe enough to require methotrexate therapy were 
evaluated to assess the effects of the drug on both liver function and histology. Thirty-five 
patients had not received methotrexate (untreated) and 35 patients had previously received 
methotrexate (treated). A total of 102 liver biopsies were performed in these 70 patients. A 
review of the liver biopsy specimens showed no statistically significant differences in the 
histologic changes between thE' treated and untreated patients. The lack of reliable correla-
tion between the liver function tests and the histologic findings noted in previous studies 
was confirmed in this study. 
In the 35 untreated patients, nondiagnostic changes were seen in the liver biopsies of 28 
patients (80%) and significant fibrosis in only L patient (3%). No biopsy showed cirrhosis. In 
the 35 treated patients, nond1agnostic changes were seen in 25 patients (71 "i l, significant 
fibrosis in 2 patients (6%), and cirrhosis in l patient (3%). Thirty-two repeat biopsies in 21 
patients showed no progression in the fibros is scores up to a period of27 months of therapy. 
thus raising douhts about the necessity of performing routine lh·er biopsies in those 
patients receiving methotrexate on an intermittent regimen. 
The reports of significant liver damage following 
methotrexate therapy for psorias is have resulted in 
a reevaluation of the use of methotrexate for this 
disease. Following the report by Coe and Bull in 
1968 Ill of postnecrotic ci rrhosis, presumably re-
lated to methotrexate therapy for psoriasis. a 
comprehensive study was undertaken at Washing-
ton University Medical Center to evaluate both 
liver function and histologic changes in liver speci-
mens obtained by needle biopsy in those patients 
requLring methotrexate to control their psoria!'l is. 
In this report we present our experience with 70 
patients in whom a total of 102 liver biopsies were 
performed from 1969 lo 1973. 
During this time period additional cases of 
cirrhosis (2-6] as well as efforts to evaluate the 
effect of methotrexate on the I i ver [7 - 13 ] have been 
reported , and the National Program for Dermatol-
ogy has established guidelines (14] for the use of 
methotrexate which include a reasonable approach 
to the problem of hepatotoxicity. Recently the 
preliminary results of an international cooperati,·e 
study were published which included the evalua -
tion of 742 liver biopsy specimens [15]. 
Our data are presented to add further informa-
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Lion concerning the effects of psoriasis and met ho-
trexate on the liver. The interpreta tion of the data 
has led us to quest ion the necessity for performing 
a routine liver biopsy when methotrexate is used on 
an intermittent regimen for the treatment of pso-
riasis. 
PATIENTS AND METHODS 
Seventy patients with psoriasis considered ~evere 
enough to require methotrexate were studied . Thirty-fi\·e 
patients had not received met hot rex ate previously (un -
treated!; the other :l5 had received methotrexate 
(treated) prior to incl usion in this study. Hepatic e\•Alua-
tion included a liver biopsy. serum alkaline phosphatase, 
SGOT, SGPT, bilirubin. a nd a BSP (normal. less than 
5'1; retention at ~5 min). Our protocol required the 
discontinuation of the methotrexate if significant histo-
logic abnorma lities were seen on liver biopsy. Patient s 
continuing to receive methotrexate were restudied a1 
intervalb of a pproximately 6 12 months. From the time of 
the initial lh•er biopsy. patient.s received further metho-
trexate in only single imermittent (intramuscular or ora l) 
but moderately high doses (25- 50 mg) as opposed to a 
continuous daily low-dose regimen wilh rest period~. In a 
few cases the divided dose, intermittent oral schedule 
over a :36-hr period {16] was used. 
Alcohol History 
We assumed that alcohol intak~ might be one nf the 
most important factors in the development of significan t 
hepatic damage. Alcohol consumption was arb itrarily 
divided mto two groups: I 1) no a lcohol to m inimal a lcohol 
inges tion (1 - 2 ounces of bard liquor per week or its beer 
equivalent). and (2) moderate to excessive alcohol inges-
tion (regular daily intake of hard liquor or beer or 
sporad ic heavy use of either). Following the init ial liver 
biopsy. patients were asked to ab~tain completely from 
alcohol and were warned that anv alcohol intake might 
lead to permanent liver damage. 
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Liuer Binp.~ie.\ 
Allli,er biop:;ies were performed by the Gastroenterol -
ogy Divit.ion usin~t the Menghini 1-sec IPchnique 1171 
with a 16-gauge aspiration needle. Slide~ were routinely 
!.tamed with hematoxylin and eo>in. Stains fur c<mnec 
tive tissue !Masson'~< trithromel were pt>rformed when 
indicated b\ the review of the hematoxylin and eosin 
btained t i~<s~es. 
· 
Sections of all 10:! liver hiopsies were re\'iewed by four 
ohservers. three sur~tical pathologi~ts ancl one l(lllitruen-
terologist !R.A.I. in two sinin~t" in a random blind 
fashion. The coded sections from those patients with 
more than one biop"y were recoded and evaluated a 
second time. Sections were waded on a 0 to I scale by 
each reviewer as outlined in Table I The four mdi,idual 
scores were added ond the sum total used in the 
mult ivariatc analysis of data. A biopsy was ronsidered to 
be normal only if the score in all categories wa~ 0 
The histologic parameter was g1'·en a score of 0 unless 
two nr more of the four observer.; indicated at least a 
grade I abnormal it} with the sum of the four observer~ 
being at least 3. Detectable abnormalitie" in any hit.to 
logic parameter g1ven a total score of less than 8 by the 
four observers (with an a\erage score of le~s than 21 were 
cons1dered to be nondia~:nostic change" r' olgnifit·nnt 
abnormality wa~ arbitrarily defined fv• any histolof!iC 
parAmeter in whi<·h the sum of the four oh,;t:t\'l?rs was 
equal to or weater than 8 (w;th an avera~:e score of 2 or 
morel. 
Stat istirol Ano/ysi., 
The iO patient>- were ranked (with groupin~l according 
to the total score (range 0 161 for each of riw hUitolugic 
parameters (hyperploid nuclei, fat. inflammation, fibro-
sis. and necrosil;) and the ranks transformed into blan-
dord normal score!>. Only the initial biops~ of each 
patient wAs used in the statistical evaluation Multivari-
ate analy~<i~ of \'&nann· (18) was employed to test the 
efferts of alcohol (no to minimal aleohol m~esuon V~>. 
moderate to exces!-. alcohol inJCI.'Stionl and methotrexate (no previous methotrexatt> therapy vs. previous metho-
trexate therapy) The eflert of ~l·hedule !continuous \'s. 
intermittent methotrexate administration) within the 
methotrexate-treated grnup wa~ analvzed separately by a 
multivariate analysis of c·ovariance in order to facilitate 
adjustment for th.e dose (in logarithms of the total dose) 
TABLE<: I 
Ciradin~: uf hi.,tu/(lpic chonJ:f'-' in lirrr biop.,;,., 
- Histol(ll(i;-r Grad~ 0 r Grade I - t Grodl' 2 1 GrnciP :t parameter 
Hyperploid I Majority of nucle1 Wide diversity in As grAde I but IM(Ist nuclei at 
nuclei of same diame- ran~e of nuclear with smallPst least 3 times the 
Grndt 4 
:-.:umerou~ very large 
bizarre nuclei 
Fat 
ter with a fe\\ I 
smaller nnd a 
few larger ( t t> .. :l 
:\one 
size~ (i.e .. mMe nuclei in minor- diameter nf 
than :1_ distmc! J ity smallest 
SIZC,.) wtlh small 
nut·le1 $1111 pre -
dam mating 
Less than fi·' uf 5-15% of hepoto 
hepatncyte:< in- cytes involved 
volved 
15 'liJ' ol hepatu- More than :10% of 
cyte~ invulved hepatucytes in-
volved 
Inflammation Less than 10 -20 IAveragt> of 20- 200 
I lymphocyte~>/ lymphocytes/ 
Average of 200-
1000 lympho-
More than 1000 
lymphocytes/ 
portal tract 
and/or occa-
sional poly., or 
eosinophiles. 
More than 3 
foci/lobule w;th 
more thon 10 
t·ells 
Connuent innumera-
ble cell~ in portal 
trart containing a 
mixture of cells or 
predominantly of 
PMi'<L'S . Widely 
dispersed or con-
nuent areas of in-
nammalion 
portaltract. portaltract. cytes/ponal 
tract. J- 3 f<l('i/ 
lobule with !l- 10 
None in lobule Rare foci of 1 -3 
Fihrosi~ :\one 
Necrosih ·de- '\one 
Ftencration j 
i 
I 
I 
I 
cells in lobule 
cells 
Percept1hle in Stellate librmds 
creasl· in fihrnus I around rentro-
cunn<'ctive ti, . lobular veins 
~ue 10 portal or · or increase in 
<'Cntral areas I portal conner-
Live ti>osue not 
sufficient tu 
connect adja-
cent land-
marks 
l'urtAI or cen ' Unifnrm fibrosi~. 
trolobulnr fibrn· connective I is5ue 
:<i~ of such ex band!. cunnectin~: 
tent as to con portal and <·entral 
nect lor hridf!el areah. cutting pa-
adJacent portal renchyma into 
or cent ral areas nodules 
but not uni-
lorml.v 
At lens1 I cell seen :! degcneratin~: 5- 10 degenNatin~t ! lS - 20 dej!ent•rating 
in sumP stage nf 
degeneration 
cells/lobult cells/lobule celh./lobule ur 
more lup to lar~e 
confl11ent arl'ns or 
foci.l 
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and duration of therapy (in lognrithms of actual duration 
of therapyl 
RESULTS 
No Previous Methotrexate Therapy (Untreated) 
and No to Minimal Alcohol Intake 
Seventeen patients were included in this group. 
Five patients (29.5%) had normal liver biopsy 
specimens by the defmition of "normar· discussed 
above. Nondiagnostic changes \\ere observed in the 
remaining 12 cases (70.5'1) including mild percep-
tible fibrosis in l patient (5.9%) (case #9). The 
BSP was abnormal in 7 of the 16 patients in whom 
it was performed (43.8%). In all 7, the values were 
less than or equal to 8.0% of t he administration 
dose of BSP at 45 min. The results in this group are 
shown in Table II. 
No Previous Methotrexate Therapy (Untreated) 
and Moderate to Excessive Alcohol Intake 
This group consisted of 18 patients. Only 1 
patient had a normal liver biopsy specimen. Non-
diagnostic changes were seen in 16 of the remaining 
patients (88.8o/r) including mild detectable fibrosis 
in 7 (38.9':t ). Significant fibrosis was seen in only 1 
patient (5.6'i!.) (case #25). The BSP was abnormal 
in 8 (50.01'() of the 16 patients in whom it was 
performed. The results in this group are shown in 
Table III. 
Preuiou.~ Methotrexate Therapy (Treated) and No 
to Minimal Alcohol Intake 
Sixteen patients were included in this group. Six 
patients (37 .5'"<) had a n<"•rmal liver biopsy speci-
men . Eight patients {50.0%} showed nondiagnostic 
TAALE II 
Gradinp nf lieer biop.~ic., in patu•nts uith no prenou.~ 
mPthotrexate themp.\ and nc• to mimmal alcnhol intake 
g~ nl 
iop'\ BSP 
Hyper· 
plmd 
nude• 
-
;"ji) 1.6 4 
22 fi.l-1 0 
:JI 2.9 I 
fi:l 6.fi :l 
li 18 5.4 2 
6 :18 6.i a 
7 :11 :l.:l :l 
·I:! 8.0 () 
:14 i.ll I 
40 2.4 0 
:16 1.-1 I 
48 2.4 () 
·IH 1.1 1 
;)9 2.:! I 
74 Z'l.i 6 
22 ;t;l tl 
;)8 n.d • 2 
· n .d . not done 
In F'nt 
m 
:l 
() 
ll 
I 
ll 
·I 
I) 
I) 
L 
0 
9 
() 
ll 
6 
:l 
;j 
I 
-
~m- F"h · atinn 1 rn!--l"-1 0 I 0 
i) () 
.j 0 
:J I 
0 
5 
2 2 
:! :l 
0 0 
() 0 
0 
I u 
3 0 
:l 0 
0 0 
5 1 
() 
0 
() 
() 
0 
0 
() 
0 
(I 
0 
0 
0 
0 
() 
() 
TABLE Ill 
Gradm:~ o[ lit•rr biopsie~ m patten/., u·1th no previiJu,, 
methotrexate therap.\ and muderate to exce.~~iue alciJhol 
intakt• 
C'nse Ane nt 
Hyper· lnflam- ~'ihrn· l\erro-BSP plnid Fat biop~y 
nude• mat ion sis !'<IS 
--r- -
--
18 45 28.7 :J 9 6 6 I 
19 24 2.9 0 0 0 0 0 
20 r;!j 2.:! 2 I 3 I I 
21 46 7.4 ) 9 :l I 0 
22 46 18.6 :1 10 5 5 1 
2:1 40 4 .:1 0 9 I 0 0 
24 48 4.1 5 () 0 0 0 
2.5 59 r..o ~ 10 8 9 2 
26 38 5.2 5 10 2 ) 1 
27 59 10.1 0 4 5 6 I 
28 28 2.5 I tJ 6 2 0 
29 :19 4..1 3 9 4 2 I 
:!0 4:! n.d.· I 1 :l ;j 0 
:u 55 :U I 4 0 () 0 
:12 48 7.ii 2 8 a :l 0 
:1a :!8 n.d. I 4 0 :! () 
:14 54 3.:1 3 9 6 I I 
!lfl 47 6.5 0 ·1 !! :l 0 
--
• n.d . not done 
histologic change5 .including mild detectable fibro-
s is in 3 ( 18.8",). Significant fibrosis was seen in 1 
patient (6.3<!1) (case #37) and 1 patient had frank 
cirrhosis (6.3C:d (case #41) . The BSP was abnormal 
in 5 of the 13 patients in whom it was performed 
(38.60f). The results in this group are shown in 
Table lV. 
The one patient in our series with cirrhosis (case 
#4 1) is a 57 -year-old male who had increasingly 
severe psor iasis since age 23. He was placed on 
daily low-dose oral methotrexate by his local 
physician in September 1967 with weekly rest 
periods of several days. This regimen was contin-
ued for approximately 2.5 years, when elevated 
liver function tests were first detected. The patient 
was hospitalized elsewhere in March 1970 and 
found to have abnormal liver enzymes. hepatomeg-
aly, and a serum bilirubin of 2.8 mg"L Methotrex-
ate was discontinued. In July 1970 the patient was 
placed on Orinase for diabetes. There was no 
history of any alcohol ingestion. The patient was 
hospitalized at Barnes Hospital in September 1970 
for treatment of his psoriasis. A liver biopsy was 
interpreted as active focal necrosis with collapse 
(scarring). BSP retention was 12.9% at 45 min . The 
patient was not considered a candidate for further 
methotrexate therapy and has since been treated 
with lar and ultraviolet light. A repeat BSP in 
October 1972 was 18.5<1·. 
Previous Methotrexat e Therapy <Treated) and 
Moderate to Exces.~iue Alcohol Intake 
This group consisted of 19 patients. Only 1 
patient {5.~'1} had a normal liver biopsy specimen. 
Seventeen patients (89.4'/r.) had only nondiagnostic 
changes which included mild detectable fibrosis in 
6 patients C:H.6<';) and s ignificant fibrosis in I 
instance {5.:N,) (case #68). No cirrhosis was seen. 
The BSP was abnormal in 6 out of 14 patients in 
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whom it was performed (42.911? ). The results in this 
group are shown in Table V. It )Should be empha-
sized that patients who may have previously been 
informed of the potential role of alcohol in inducing 
hepatic abnormalities might tend to falsify their 
history in the hope of obtaininK methotrexate. In 
one case (#70) the liver biopsy was histologically 
consistent with acute alcoholic hepatitis in spite of 
the patient 'R denial of any alcohol intake. 
Follow-up Biopsie.~ 
Twenty-one patients were rebiopsied at least one 
time for a total of 32 repeat biopsies. The interval 
between biopsies was from 6 27 months (average 
12.4 months). No additional methotrexate was 
given between the tirst and second liver biopsies in 
3 patients (cases i 66, 68, 69) because of fear of 
significant liver damage. In retrospect the original 
biopsies in these 3 patients did not justify with-
holding methotrexate. and methotrexate was re-
sumed in 2 of the 3 cases. The average dose of 
methotrexate between biopsies in the remaining 28 
biopsies was 823 mg. No patient showed any 
progression in the fibrosis score in this group of 
follow-up biopsies. 
A complication of liver biopsy occurred in 1 
patient who developed an inRidiou)S bleed post -
biop)Sy eventually requiring a laparotomy. The 
patient 's recovery from surgery was uneventful. 
In only 2 cases, #18 and #41. were the bilirubin 
and liver en1.yme value):; abnormal. Case #18, an 
alcoholic, was not placed on methotrexate. Case 
#41 wM the only patient in this series with cirrho-
sis. 
The results of the multivariate analysis show no 
stati!ltically significant (p 0.4) effect of metho-
trexate treatment (vs. untreated) tn the liver biopsy 
specimens. On the other hand. there is a statisti-
cally significant (p < 0.001) effect of alcohol intake 
on the histology of the biopsy specimens. This 
difference is attributable largely to the fat score 
and to a lesser extent the fibrosis score. However. 
when analyzed separately, the combination of 
moderate to excess alcohol plus previous metho-
trexate therapy did not show a significantly greater 
tendency to,,·ard fat or fibrosis than the other 
groupings. 
The results of the analysis for the schedule of 
administration of methotrexate after adjustinl't for 
dose and duration of therapy are only suggestive ( p 
0.02) of the possibility that continuous therapy 
at any given total dose and therapy duration, 
results in more hyperploid nuclei and to some 
extent fibrosis. This is in contrast to the intermit-
tent regimen in which there is no evidence of 
hepatic damage. In the analyses of the schedule of 
administration we were able to compare the two 
regimens in only 31 of 35 patients because of 
insufficient data in 2 patient!\ and a combination of 
regimens in 2 other~. 
DISCUSSION 
The present report outlines the Washington 
University Medical Center's experience on the 
effects of methotrexate on the liver in 70 patients 
with pgoriasis requiring methotrexate for control of 
the disease. Based on the results of the analysis of 
the data obtained from 102 liver biopsies, the 
decision was made to stop the study, especially its 
prospective nature. A review of the specimens from 
102 biopsies failed to Fohow sufficient evidence of a 
significant association between methotrexate, 
when administered on an intermittent basis. and 
hepatic fibrosis to justify continued routme hver 
biopsies in this institution. If the abnormalities 
that are of major concern, i.e., fibrosis and cirrho-
sis, occur gradually and are slowly progressive, a 
careful study of the changes seen in our biopsies, 
TAHLE I\ 
GradmN of IH•er biapsie., in patll'nts rrith pr(•t•i(}ll,, m ethutn•xaiP therapy (treated) and no to minimal alcohol intak l· 
Cosr 
36 
:n 
38 
39 
40 
41 
42 
4:1 
44 
45 
46 
47 
48 
49 
50 
51 
ARe ut 
binp, y 
-
:lU 
illl 
36 
67 
:! I 
Iii 
li·l 
:I:\ 
21-1 
56 
22 
24 
ij.j 
12 
27 
~ll 
Total 
dose !mill 
-
525 
5000 
650 
5000 
1875 
1125 
3121i 
:moo 
:moo 
960 
2275 
5:12 
1250 
n.a. 
2000 
3000 
Schedule' Duration t1l Rxt,·elli'SI 
r-.. --1-
I 0.5 
C/1 8 
I 0.5 
c i) 
I 1.5 
c 2.5 
I 3.5 
C/1 4.0 
I 3.0 
c 4.0 
(' :l.O 
I 0.5 
c 2.0 
11.11 . n.a. 
c fi.O 
c 5.0 
HSP II yperplnid nucfpi Fnt 
- --
1.6 0 0 
n.d. 6 II 
:ts 1 0 
7.H :l 2 
4.:1 I 0 
12.9 6 0 
n.d. 3 0 
2.6 0 4 
2.7 0 4 
4.:1 2 I 
5.6 5 0 
n .d . 0 0 
SA .. 1 
1.1 2 0 
:to 2 0 
i .. ~ 8 i) 
• I intermittent: C = continuous: n.d . - not done: n.u. - not a\'uilable 
lnllammn, Fihro'i' ~ecrnsi!' tion 
~-
I 0 0 
3 9 4 
I I 0 
I 4 0 
I 0 0 
13 16 7 
2 I 0 
1 0 0 
I 0 () 
0 0 0 
5 6 0 
I I 0 
1 0 0 
:1 3 1 
0 0 1 
4 2 0 
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!'ABLE V 
Ciradin!la/ lit·er biopMe.~ 111 patit·nl\ with prt'l'IIJLL,, m f'lh(}trexau·thcrapy !tn·atedl and moderate to rxn•Mire alcohol 
intake 
(·moe A)!e&t Total SrhPdule' Dura1111n of HSP HyJI{'TI!lld f'n t ~t.•trc•!<oi~ bioJl"' ciu"\('(mgl Rxlwar,) OUC' e1 
52 ~ 12.'\11 ;I.() n.d . I 4 I :1 0 
53 64 ;j(J()(l -1.() n.cl. R 0 :l 2 0 
54 42 221i O.li I 1.2 12 :I 2 
;;,:; 48 191it1 3.0 5.0 {) :I 0 0 
56 :~') 'li50 :to n .cl. i 0 .j 0 0 
fii 39 141ll l. i) :!.5 :! 9 0 0 
!'IR :!8 tRO 0.5 6.6 0 5 '2 I 0 
;)9 40 2500 3.0 n.d . 0 0 0 0 0 
60 :!4 n.a. n.a. :to :!.9 :l i 4 
61 58 100 r o.:l 7.0 II 4 4 
6:! 40 '2000 r :!.0 :!.:1 :1 5 :I :l 
6:1 69 :l'200 ( .'i.O !l.i 4 i 2 '2 
6·1 48 ~~~ I 6.0 :1.r> (i n 6 '2 () s.:; ·18 (' 2.0 .'),ii I 6 6 :3 61) 61 79'2 I 1.0 R.:l () 6 0 2 6i 2.') l5:10 (. 50 :ul I 10 :! 1 () 
6S 3i 1680 c :l.o n.d . 6 4 !l 10 2 
6!l '29 li50 c 6.0 :l.O .J 4 5 (I () 
iO 3i 6·10 c J{) :!.0 I 6 6 6 I 
'I intermittent: (' conunuous: n.cl . mll dnne: n.a . not a'·uilahle 
which were numerically graded, should have al -
lowed u~ to confirm this possibility. 
A retrospective analysis of the initial liver biopsy 
of the 70 patients showed no s ignificant differences 
in the histologic changes between the treated and 
untreated patients. The total score!'. for each ht!;to-
logic pa rameter l)f all four ob!'.ervers were used in 
the multivariate analysis of these data. thus elimi-
nating any distort ion of trends produced by classi-
fy ing histologic changes int<J nondiagnostic and 
SiJ{flificant abnormalities. Of particular impor-
tance was the finding that the :32 repeat liver 
biopsy ~pecimens in 21 patient s showed no progres-
SI<>n of any of thel'>e chang~. 
There remains the alternate possibility tha t the 
development of c·i rrhosis from methotrexate occurs 
only infrequently und/or i~ the result of rapid , 
massi,·e. catastrophic morphologic change which 
will only be found by monitoring patients with 
frequent serial liver biopsies. However. on the basis 
of our findings, a prospecti,•e study in which it 
would be necessary to perform approximately GOO 
additional liver biopsies would be required to 
confirm statistically the low incidence of cirrhosis 
observed in the series. 
The findings of the international cooperative 
s tudy [15 ) have reconfirmed our decis ion to discon-
tinue a protocol of routine repeat liver biopsies. In 
their analysis of 200 pre-methotrexat e patient::;, the 
incidence of cirrhosis was I .5"; and in :372 post -
methotrexate patients it was 2.7'l. They concluded 
that the incidence of cirrhosis in t he patients was 
no greater than the incidence of cirrhosis in a la rge 
combined series of 56.799 consecutive hospital 
autopsy examination~ i:l.0411, ). ln addition. 81 
patients in their series who had two sequential 
biops ies while continuing to receive methotrexate 
showed no progress ion of fibrosis. 
Of special interest is the high incidence of 
apparently abnormal but nondiagnostic changes 
seen in the liver biopsy specimens of patients with 
psoriasis. In the 3;; untreated patients, these non -
diagnostic changes were seen in 80', of the biop-
sies. In add it ion. 71.417k of the treated cases showed 
similar changes. It should be emphasized that the 
incidence of such changes in a ser ies of normal 
control needle liver biopsy specimens is not known 
nor is it likely that it will be determined in the near 
future. Such data would not justify the risks 
associated wnh performing liver biopsies in normal 
control subjects which would be necessary to 
obtain Kuch information . The arbitra ry classifica-
tion of nondiagnostic and significant a bnormalities 
used in the course of thil'> studv were necel.isary for 
the routine management of ou; patient~ before the 
statistical analysis wa~ completed. Thus, the s ig-
nificance of the nondiagnostic changes remains 
unknown . 
Our a nalys is of the schedule of methotrexate 
admini:. tration was limited by the small number of 
patients in the s tudy . As methotrexate was admin-
istered only intermittent!} a fter the initial biopsy 
in the prospective portion of this s tudy, our inter-
pretation of the indications for liver biopsies refers 
only to methotrexate administered by an intermit-
tent schedule. 
The role of alcohol in the production of hepatic 
fibrosb in methotrexate-treated patients remains 
unclear. The lack of correlation of liver changes in 
our series in the methotrexate-plus-alcohol group 
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of subject!\ may he due to the small number of 
patients, to the difficulty in obtaining an acrurate 
his tory of alcohol intake from the potient!i, or to 
the fact that some individuals did indeed discon-
tinue alt-ohol intake before their liver biopsy. The 
series of Dahl et ul [10] and Roenigk et al [81 hove 
indicated that alcohol is not a nere.,:.ary prerequi-
site to the development of significant hepat tt' 
abnormalities from methotrexate Case #41 (Table 
IV) represents our onlv experience with cirrhosis. 
This patient was not under our l·are until the 
process was present. "ievert he less this case as well 
as the others in the literature speak strongly for 
the ability of methotrexate tn cause cirrhosis in the 
ab:.ence of alcohol ingestion 
Weins tein et al [7] pointed out the need to 
distinguish between portal or micronodular cirrho· 
sts and postnecrottc or macronodular cirrho,b. 
Many hepatologi~;ts feel that the hepatic injury 
resulting from alcohol may eventuate, in some 
cases. in macronodular rirrhosi.s [HI[. tbu,. elimi-
nating the ,-aJiditv for the distinction between 
these two types of cirrhos1R m assessing the rule of 
methotrexate in producing one form of cirrhnsis 
While it ~oeems reasonable to assume that the 
adverse effect of alcohol on the liver may be 
synergistic with the potential hepatotoxic action of 
methotrexatl'. more data are needed. It mav well 
be that these two agents are hepatotoxic by differ-
ent and nonsynergisttr mechanisms. It is also clear 
that fihrosts and e\en cirrhosts can he pre!-oent tn 
the absence of abnormalli"cr function re:>ts (15). 
Even BSP retent mn as a sensit i\'t• test of liver 
function has been discarded in n recent series [20 ]. 
C'ase #2.5 in this series iiiU!-.trntes this prohlem. 
Significant fibrosis wa::. seen tn the liver biopsy 
specimen in spite of normal liver function tests 
including the SSP retention Although the que~­
t ion as to whether a liver biClp~y prior to met ho-
trexate therapy is necessary in nrder to avoid 
treating a patient with fibrnsis cannot be answered 
at this time. it ts of interest that when cast: h'25 
eliminated the ingestion of all alcohol. the del(ree 
of fibrosis impro\ed markedly in !-opite ol the 
administration of methotrexate on an interrntt-
tent-dosage .schedule. 
The morbidity resulting from li\'('r biop!>,\' has 
been virtually ignored in all r.tudii:'S tu date dealing 
with Lhe effect of methotrexate on the liver. The 
mcidence of significant post-biopsy bleedinJ;:: from 
a needle biopsy of the liver in this medical center is 
approximately 0.5~ . or 1 in :mo. While no fatalities 
have occurred in this Center as a result of this 
procedure, a lapamtomy was neceN nry to control 
bleeding in the one major <'omplit•ation encoun-
tered in this stud) 
Having weighed the risk of liver hiopsy against 
the informatton to be gained from ruutine prosper-
ti\'e liver biopsies bl'fore methotrexatc therap\, we 
find the need for such a procedure to be question-
able at this time. Lin til there are lon~-term data 
available regarding the incidence of hepatic fthro-
sis from intl'rmiltent methotrexate administration 
from a large seriel' of patients, the indications lor 
liver biup!iy in each cas<' should be indi\'idualized 
to tho~e patients in whom pnst or present liver 
disease is suspected. 
Note added in proof 
~ince this !'tudy was t·ompleted one additional 
lt\er biopsy WH!-. performed. The- procedure r<'-
sulted in n significant postbiopsy bleed which 
li>rtunateh· wns controlled withnut the necessity 
for a lapa;otomy. 
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